Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma

Surgery

Volumn 136, Issue 2, 2004, Pages 205-209

  Kirman, Irena ^a,b   Poltoratskaia, Natalia ^a   Sylla, Patricia ^a   Whelan, Richard L ^a  

^a New York NY ^*  (United States)

^b BB1716 New York NY 10032 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; RECOMBINANT PROTEIN; SODIUM CHLORIDE; SOMATOMEDIN BINDING PROTEIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; COLON CARCINOMA; COLON MUCOSA; CONTROL GROUP; CONTROLLED STUDY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXPERIMENTAL NEOPLASM; FEMALE; IN VIVO STUDY; ISOGRAFT; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE; TUMOR VOLUME; WILD TYPE;

ADENOCARCINOMA; ANIMALS; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS;

EID: 3843126397     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2004.04.020     Document Type: Article

References (20)

1. Kirman I., Cekic V., Poltaratskaia N., Asi Z., Bessler M., Huang E.H., Forde K.A., Whelan R.L. Plasma from patients undergoing major open surgery stimulates in vitro tumor growth: lower insulin-like growth factor binding protein 3 levels may, in part, account for this change. Surgery. 132:2002;186-192
2. Cubbage M.L., Suwanichkul A., Powell D.R. Insulin-like growth factor binding protein-3. Organization of the human chromosomal gene and demonstration of promoter activity. J Biol Chem. 265:1990;12642-12649
3. Hong J., Zhang G., Dong F., Rechler M.M. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem. 277:2002;10489-10497
4. Valentinis B., Bhala A., DeAngelis T., Baserga R., Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol. 9:1995;361-367
5. Reeve J.G., Kirby L.B., Brinkman A., Hughes S.A., Schwander J., Bleehen N.M. Insulin-like growth-factor-binding protein gene expression and protein production by human tumour cell lines. Int J Cancer. 51:1992;818-821
6. Grimberg A. P53 and IGFBP-3: apoptosis and cancer protection. Review. Mol Genet Metab. 70:2000;85-98
7. De Benedetti F., Meazza C., Oliveri M., et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology. 142:2001;4818-4826
8. Kirman I, Poltaratskaia N, Cekic V, Forde K, Ansari P, Boulay C, Whelan RL. Depletion of circulating insulin-like growth factor binding protein 3 following open surgery is associated with high IL-6 levels. Dis Colon Rectum. In press.
9. Gill Z.P., Perks C.M., Newcomb P.V., Holly J.M. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem. 272:1997;25602-25607
10. Boyle B.J., Zhao X.Y., Cohen P., Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha, 25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol. 165:2001;1319-1324
11. Cohen P., Lamson G., Okajima T., Rosenfeld R.G. Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol Endocrinol. 7:1993;380-386
12. Ma J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens C.H., Stampfer M.J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 91:1999;620-625
13. Palmqvist R., Hallmans G., Rinaldi S., Biessy C., Stenling R., Riboli E., Kaaks R. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut. 50:2002;642-646
14. Modric T., Silha J.V., Shi Z., Gui Y., Suwanichkul A., Durham S.K., Powell D.R., Murphy L.J. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice. Endocrinology. 142:2001;1958-1967
15. Salahifar H., Baxter R.C., Martin J.L. Insulin-like growth factor binding protein (IGFBP)-3 protease activity secreted by MCF-7 breast cancer cells: inhibition by IGFs does not require IGF-IGFBP interaction. Endocrinology. 138:1997;1683-1690
16. Manes S., Llorente M., Lacalle R.A., Gomez-Mouton C., Kremer L., Mira E., Martinez- A.C. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem. 274:1999;6935-6945
17. Irwin J.C., Suen L.F., Cheng B.H., Martin R., Cannon P., Deal C.L., Giudice L.C. Human placental trophoblasts secrete a disintegrin metalloproteinase very similar to the insulin-like growth factor binding protein-3 protease in human pregnancy serum. Endocrinology. 141:2000;666-674
18. Claussen M., Kubler B., Wendland M., Neifer K., Schmidt B., Zapf J., Braulke T. Proteolysis of insulin-like growth factors (IGF) and IGF binding proteins by cathepsin D. Endocrinology. 138:1997;3797-3803
19. Papanikolaou A., Wang Q.S., Papanikolaou D., Whiteley H.E., Rosenberg D.W. Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis. 21:2000;1567-1572
20. Papanikolaou A., Wang Q.S., Delker D.A., Rosenberg D.W. Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett. 14130:1998;29-34